six The phosphodiesterase-5 inhibitor sildenafil is certified for PAH in FC I–IV inside the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which includes bosentan, sitaxentan and ambrisentan are oral therapies certified to be used in PAH. As no oral agent has proven superiority there remains discussion as to which